BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23930349)

  • 1. Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.
    Salam MA; Siddiqui MA; Nabi SG; Bhaskar KR; Mondal D
    J Health Popul Nutr; 2013 Jun; 31(2):294-7. PubMed ID: 23930349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced case of PKDL due to delayed treatment: A rare case report.
    Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Miltefosine Induced Reduced Male Fertility Capacity after Treatment of Post Kala-azar Dermal Leishmaniasis, Bangladesh.
    Basher A; Rashid MM; Habibullah AM; Nath R; Akter D; Chowdhury IH; Azim A; Nath P; Faiz MA
    Mymensingh Med J; 2019 Apr; 28(2):328-332. PubMed ID: 31086147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
    Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
    J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.
    Hasan MM; Proma SB; Hossain MS; Arifuzzaman M; Islam N; Siddique MAB; Amiruzzaman
    BMC Infect Dis; 2023 Dec; 23(1):885. PubMed ID: 38110894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
    Sundar S; Singh A; Chakravarty J; Rai M
    ScientificWorldJournal; 2015; 2015():414378. PubMed ID: 25685839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
    J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol.
    Mondal D; Hasnain MG; Hossain MS; Ghosh D; Ghosh P; Hossain H; Baker J; Nath R; Haque R; Matlashewski G; Hamano S
    BMJ Open; 2016 May; 6(5):e010050. PubMed ID: 27188804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
    Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
    Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report: Treatment of Widespread Nodular Post kala-Azar Dermal Leishmaniasis with Extended-Dose Liposomal Amphotericin B in Bangladesh: A Series of Four Cases.
    Basher A; Maruf S; Nath P; Hasnain MG; Mukit MA; Anuwarul A; Aktar F; Nath R; Hossain AA; Milton AH; Mondal D; Mohammad Sumsuzzaman AK; Rahman R; Faiz MA
    Am J Trop Med Hyg; 2017 Oct; 97(4):1111-1115. PubMed ID: 28820697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL).
    Wijnant GJ; Moulik S; Chatterjee K; Das NK; de la Flor R; Van Bocxlaer K; Croft SL; Chatterjee M
    Exp Parasitol; 2024 Feb; 257():108687. PubMed ID: 38114040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.
    Hasnain G; Shomik MS; Ghosh P; Rashid MO; Hossain S; Hamano S; Mondal D
    Am J Trop Med Hyg; 2016 Dec; 95(6):1383-1385. PubMed ID: 27672208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy.
    Belay AD; Asafa Y; Mesure J; Davidson RN
    Ann Trop Med Parasitol; 2006 Apr; 100(3):223-7. PubMed ID: 16630379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.
    Ghosh S; Das NK; Mukherjee S; Mukhopadhyay D; Barbhuiya JN; Hazra A; Chatterjee M
    Am J Trop Med Hyg; 2015 Oct; 93(4):767-9. PubMed ID: 26175030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient.
    Abongomera C; Battaglioli T; Adera C; Ritmeijer K
    Int J Infect Dis; 2019 Apr; 81():221-224. PubMed ID: 30790722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.